TB-500 versus thymosin beta-4: fragment and parent
Understand why TB-500 and full-length thymosin beta-4 need separate evidence records, including the limits of transferring an ophthalmic trial to a fragment.
The cited TB-500 analytical study identifies an N-acetylated seven-residue fragment. Full-length thymosin beta-4 is a different molecular form. Keep the sequence, formulation and study setting attached to each reference.
Identify what TB-500 means in the source
Ho and colleagues identified N-acetylated LKKTETQ in a preparation called TB-500 and developed an analytical method for equine samples. This is evidence about the studied fragment and its detection, not a human treatment trial.
Because a market name can be used loosely, the article’s identity should not be assumed for an unrelated sample. Ask for its sequence, terminal modification and identity result before using this paper as a matching reference.
Source context: Ho et al.: identification of TB-500 in equine samples.
Keep the ophthalmic study in its own setting
The cited thymosin beta-4 clinical paper concerns an ophthalmic formulation and a dry-eye study setting. It does not describe testing the short TB-500 fragment as an interchangeable product. The molecule, formulation and question all belong in the evidence record.
A headline that combines the fragment’s name with the ophthalmic study’s outcome has skipped those distinctions. Follow the original source and restore the missing context before deciding what the study can support.
In the 72-participant randomized, placebo-controlled Phase II study, neither primary endpoint differed significantly between groups at the specified day-29 visit. The abstract reports differences on some secondary endpoints. Keep both statements in a summary; a secondary finding does not erase the primary result or establish an effect for TB-500.
Source context: Sosne and Ousler: thymosin beta-4 ophthalmic trial.
Compare documents rather than product names
Create separate columns for the fragment and full-length parent. Add rows for sequence length, terminal form, formulation, model, measured outcome and source. Where the study does not report an item you need, mark it as a question rather than borrowing it from the other column.
Monday’s Atlas labels TB-500 and thymosin beta-4 separately. The comparison tool keeps their source lists separate as well. This organization is useful for reading; it does not authenticate a sample or establish that a supplier’s material matches a published preparation.
| Field | TB-500 reference | Thymosin beta-4 reference |
|---|---|---|
| Material in the source | N-acetylated LKKTETQ fragment. | Thymosin beta-4 in an ophthalmic formulation. |
| Study setting | Analytical detection in equine samples. | Human dry-eye study. |
| What to carry into a note | Exact fragment identity and analytical scope. | Exact formulation, population and measured outcomes. |
| Result to preserve | An analytical detection method; not a human efficacy test. | Neither primary endpoint differed significantly at day 29; some secondary endpoints did. |
| What not to infer | Human efficacy from an analytical detection study. | An interchangeable effect for a different fragment or preparation. |
Source context: Ho et al.: identification of TB-500 in equine samples; Sosne and Ousler: thymosin beta-4 ophthalmic trial.
Preserve the limits when sharing research
A shareable note should identify the compound in the paper, the setting and the specific question tested. Avoid substituting a broader claim such as “studied in humans” for those details. Another reader needs enough context to follow the same source and reach a bounded interpretation.
If you receive a report labeled only TB-500, ask whether it describes a fragment or full-length material and request the supporting identity specification. Keep any clarification beside the original report. Do not silently relabel the document yourself.
Your reading checklist
- Identify the sequence and terminal modification.
- Keep the fragment separate from the full-length parent.
- Record the formulation and study setting.
- Do not transfer an ophthalmic result to a different preparation.
This is a reading aid, not a laboratory certification or a treatment recommendation.
Keep fragment and parent in separate columns
The comparison opens with both records selected. Continue into a comparison pack with those selections intact, then bookmark the records you want to revisit.
The tools are free to use. An account is optional for saving research.
Common questions
Are the names interchangeable?
They should not be treated as interchangeable structural specifications. Identify the actual molecule in each source and sample record.
Does an analytical detection study establish a clinical benefit?
No. Detecting a compound in a particular sample setting answers an analytical question, not whether a treatment benefits people.
Sources and scope
Organizational byline · AI-assisted preparation · No independent clinical review
Sources checked . Prepared with AI assistance. The original study abstracts were checked through Europe PMC on 28 September 2026. This check did not include a new independent clinical review or a systematic review of all thymosin research.
- Ho et al.: identification of TB-500 in equine samples
An analytical study identifying an acetylated fragment and its metabolites; not a human efficacy trial.
- Sosne and Ousler: thymosin beta-4 ophthalmic trial
A 72-participant ophthalmic study. Neither primary endpoint differed significantly at day 29; some secondary findings were reported. Results do not establish fragment efficacy.
Read the editorial policy or suggest a correction.
Publication history
- : First publication.
- : Added a source-scope table, the trial’s negative primary-endpoint finding, and contextual comparison links. Rechecked both original abstracts through Europe PMC; no independent clinical review.